Community Series - Liver Fibrosis and MAFLD: from Molecular Aspects to Novel Pharmacological Strategies, Volume II

Book excerpt: This Research Topic is the second volume of the Community Series, Liver Fibrosis and MAFLD: from Molecular Aspects to Novel Pharmacological Strategies. Please find the first Edition here. Metabolic disorders, such as obesity and type 2 diabetes mellitus, represent a critical health problem. This is mainly due to the economic cost of health services supporting the treatment for these patients of both primary and secondary disorder effects. Fatty liver damage associated with metabolic dysfunction is currently called Metabolic Associated Fatty Liver Disease (MAFLD), a new concept proposed in 2020, which affects a quarter of the population worldwide and is characterized by liver fat accumulation and all the repercussions that this may bring, such as inflammation, fibrosis, cirrhosis and in some cases, hepatocellular carcinoma.